Checkpoint Therapeutics Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Checkpoint Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: CKPT
TL;DR
Checkpoint Therapeutics (CKPT) filed an 8-K detailing financial results and operations.
AI Summary
Checkpoint Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 95 Sawyer Road, Suite 110, Waltham, MA 02453.
Why It Matters
This 8-K filing provides investors with crucial updates on Checkpoint Therapeutics' financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate material changes or risks.
Key Players & Entities
- Checkpoint Therapeutics, Inc. (company) — Registrant
- May 13, 2025 (date) — Date of earliest event reported
- 95 Sawyer Road, Suite 110, Waltham, MA 02453 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Checkpoint Therapeutics, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 13, 2025.
Where are Checkpoint Therapeutics, Inc.'s principal executive offices located?
Checkpoint Therapeutics, Inc.'s principal executive offices are located at 95 Sawyer Road, Suite 110, Waltham, MA 02453.
What is the company's telephone number?
The company's telephone number is (781) 652-4500.
In which state was Checkpoint Therapeutics, Inc. incorporated?
Checkpoint Therapeutics, Inc. was incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Checkpoint Therapeutics, Inc..